Brief: Sprint Bioscience Q1 Operating Loss Narrows To SEK 3.7 Mln
May 8 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q1 NET SALES SEK 17.9 MILLION VERSUS SEK 0 MILLION YEAR
AGO
* Q1 OPERATING LOSS SEK 3.7 MILLION VERSUS LOSS SEK 12.3
MILLION
YEAR AGO
Source text for Eikon: ID:nMFN3qgjFd
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln